Cargando…

Phase II study of gemcitabine in patients with advanced pancreatic cancer.

The efficacy and safety of gemcitabine at a starting dose of 800 mg m2 administered once a week for 3 weeks with 1 week's rest was investigated in chemonaive patients with advanced and/or metastatic pancreatic cancer. Of 34 patients, 32 were evaluable for efficacy, 20 patients had metastatic st...

Descripción completa

Detalles Bibliográficos
Autores principales: Carmichael, J., Fink, U., Russell, R. C., Spittle, M. F., Harris, A. L., Spiessi, G., Blatter, J.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1996
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074288/
https://www.ncbi.nlm.nih.gov/pubmed/8554969